Boehringer/Pfizer Spiriva review
Boehringer-Ingelheim/Pfizer's Spiriva (tiotropium) will be reviewed by FDA's Pulmonary-Allergy Drugs Advisory Committee Sept. 6. The NDA for the treatment of chronic obstructive pulmonary disease was submitted Dec. 13, 2001 (1"The Pink Sheet" Dec. 24, 2001, p. 18). The meeting will be at the Holiday Inn in Gaithersburg, Md., at 7:30 a.m. [To view a webcast/video broadcast of this meeting, visit FDAAdvisoryCommittee.com]...
You may also be interested in...
Pfizer's updated pregabalin NDA filing schedule calls for three initial indications - add-on epilepsy, neuropathic pain and generalized anxiety disorder - to be submitted in 2002
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.